Monopar Therapeutics (MNPR) EBIT (2017 - 2025)

Monopar Therapeutics has disclosed EBIT across 9 years of filings, most recently posting -$4.1 million for Q3 2025.

• EBIT for Q3 2025 came in at -$4.1 million, down 159.89% year-over-year; the trailing twelve-month figure through Sep 2025 was -$12.1 million (down 69.49% YoY), and the FY2024 annual result was -$15.6 million, down 419.13% from the prior year.
• EBIT came in at -$4.1 million for Q3 2025 at Monopar Therapeutics, down from -$3.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.6 million in Q3 2024 to a low of -$4.1 million in Q3 2025.
• The 5-year median for EBIT is -$2.5 million (2022), against an average of -$2.5 million.
• Across the five-year window, EBIT surged 31.75% in 2024 and plunged 159.89% in 2025, its largest moves.
• Monopar Therapeutics' EBIT stood at -$2.7 million in 2021, then dropped by 8.5% to -$2.9 million in 2022, then advanced by 28.98% to -$2.1 million in 2023, then advanced by 23.77% to -$1.6 million in 2024, then slumped by 159.89% to -$4.1 million in 2025.
• The last three EBIT figures came in at -$4.1 million (Q3 2025), -$3.2 million (Q2 2025), and -$3.2 million (Q1 2025), per Business Quant data.